Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

From the bench to the bed: individualizing treatment in non-small-cell lung cancer.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico - 1 Feb 2006

Santarpia Mariacarmela, Altavilla Giuseppe, Salazar Fernanda, Tarón Miquel, Rosell Rafael

Abstract excerpt

At the time of diagnosis, half of lung cancer patients have advanced incurable disease. Different chemotherapy combinations--with or without targeted therapies--yield similar results in spite of the continuous efforts of clinicians. However, molecular biological studies have already shed a great...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to 14-3-3 Proteins
Share to Benzamides
Share to Erlotinib Hydrochloride

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genes, cdc

Share to Genes, erbB-1

Share to Imatinib Mesylate

Share to Piperazines

Share to Quinazolines

Source

Identifiers

PMID: 16632419
DOI: 10.1007/s12094-006-0161-2

Genes

BRCA1
EGFR
ERCC1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-16632419-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

From the bench to the bed: individualizing treatment in non-small-cell lung cancer.PMID 16632419Read ↗

Predicting the outcome of chemotherapy for lung cancer.Semantic proximity Read ↗

Treatment of non-small-cell lung cancer and pharmacogenomics: where we are and where we are going.Semantic proximity Read ↗

Personalizing therapy in advanced non-small cell lung cancer.Semantic proximity Read ↗

Pharmacogenetics of conventional chemotherapy in non-small-cell lung cancer: a changing landscape?Semantic proximity Read ↗

The place of targeted therapies in the management of non-small cell bronchial carcinoma. Molecular markers as predictors of tumor response and survival in lung cancer.Semantic proximity Read ↗

Individualized therapy for patients with non-small cell lung cancer: emerging trends and challenges.Semantic proximity Read ↗

Optimization of genetics to create therapies for metastatic (stage IV) non-small-cell lung cancer.Semantic proximity Read ↗

Pharmacogenomics and targeted therapy of cancer: Focusing on non-small cell lung cancer.Semantic proximity Read ↗

Lessons learned from lung cancer genomics: the emerging concept of individualized diagnostics and treatment.Semantic proximity Read ↗

Genetics and biomarkers in personalisation of lung cancer treatment.Semantic proximity Read ↗

Customized treatment in non-small-cell lung cancer based on EGFR mutations and BRCA1 mRNA expression.Semantic proximity Read ↗

Integration of molecular profiling into the lung cancer clinic.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.